The Institute for Clinical and Economic Review (ICER) promotes itself as “the nation’s drug pricing watchdog.” However, as documented in the first of a series of PRI reports, ICER’s cost-effectiveness analyses contain inappropriate methodologies and subjective judgments in determining the value of medicines. In this podcast, PRI senior fellow Wayne Winegarden discusses why ICER’s reports contain biased, inaccurate assumptions.
Listen on these platforms:
Share this episode:
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
